Hyperthyroidism – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyperthyroidism – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Radiofrequency Ablation and Sodium Iodide (131I) for Treating Hyperthyroidism in Patients with Overactive Thyroid Nodules https://clinicaltrials.eu/trial/study-comparing-radiofrequency-ablation-and-sodium-iodide-131i-for-treating-hyperthyroidism-in-patients-with-overactive-thyroid-nodules/ Wed, 29 Apr 2026 15:03:42 +0000 https://clinicaltrials.eu/trial/study-comparing-radiofrequency-ablation-and-sodium-iodide-131i-for-treating-hyperthyroidism-in-patients-with-overactive-thyroid-nodules/ This clinical trial is focused on studying the treatment of hyperthyroidism caused by solitary autonomous thyroid nodules. Hyperthyroidism is a condition where the thyroid gland is overactive, producing too much thyroid hormone. The study compares two treatments: ultrasound-guided radiofrequency ablation and radioactive iodine therapy. Radioactive iodine, also known as sodium iodide (131I), is a chemical substance used to treat hyperthyroidism by reducing the activity of the thyroid gland.

The purpose of the study is to compare the effects of these treatments over one year, particularly looking at the occurrence of a condition called irreversible hypothyroidism, where the thyroid becomes underactive. Participants will receive either the radiofrequency ablation or the radioactive iodine treatment. The study will monitor various health outcomes, including thyroid function, nodule size, and quality of life, at different intervals over the course of a year.

Throughout the study, participants will undergo regular check-ups to assess their thyroid function and overall health. The study aims to provide valuable information on the effectiveness and safety of these treatments for managing hyperthyroidism caused by solitary thyroid nodules. This research could help improve treatment options and outcomes for individuals with this condition.

]]> Study on Preoperative Aqueous Iodine Solution for Patients with Hyperthyroidism Due to Graves’ Disease and Toxic Nodular Goiter https://clinicaltrials.eu/trial/study-on-preoperative-aqueous-iodine-solution-for-patients-with-hyperthyroidism-due-to-graves-disease-and-toxic-nodular-goiter/ Wed, 29 Apr 2026 15:00:36 +0000 https://clinicaltrials.eu/trial/study-on-preoperative-aqueous-iodine-solution-for-patients-with-hyperthyroidism-due-to-graves-disease-and-toxic-nodular-goiter/ This clinical trial is focused on studying the effects of a treatment for Hyperthyroidism, specifically in conditions known as Graves’ disease and toxic nodular goiter. The treatment being tested is a solution called Lugol’s solution, which contains iodine. The purpose of the study is to determine if this iodine solution can be safely used in patients with toxic nodular goiter and to see how it affects thyroid hormones and overall health. Additionally, the study aims to find out if using Lugol’s solution before surgery can reduce the risk of a temporary condition called hypoparathyroidism after the surgery.

The study is divided into two parts: a pilot study and a main study. In the pilot study, participants with toxic nodular goiter will receive the iodine solution for 10 days. During this time, researchers will monitor changes in thyroid hormone levels and heart rate. In the main study, participants with either toxic nodular goiter or Graves’ disease who are scheduled for thyroid surgery will receive the iodine solution before their operation. The researchers will then observe if there is a reduction in the risk of temporary hypoparathyroidism after the surgery.

Throughout the study, participants’ quality of life will also be evaluated. The main study will additionally look at the occurrence of permanent hypoparathyroidism and any issues with the nerves that control the voice, known as recurrent nerve palsy, both temporarily and permanently. The study is expected to continue until August 2025, with the aim of providing valuable insights into the preoperative use of iodine solution in these thyroid conditions.

]]>